Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
Abstract Background The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epitheli...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-5180-1 |
id |
doaj-c7bf734d511e401a9cedd3755dfa4a9a |
---|---|
record_format |
Article |
spelling |
doaj-c7bf734d511e401a9cedd3755dfa4a9a2020-11-25T01:10:09ZengBMCBMC Cancer1471-24072018-12-011811910.1186/s12885-018-5180-1Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca0Giorgia Gurioli1Lorena Rossi2Emanuela Scarpi3Cristian Lolli4Giuseppe Schepisi5Alberto Farolfi6Delia De Lisi7Valentina Gallà8Salvatore Luca Burgio9Cecilia Menna10Andrea Amadori11Lorena Losi12Dino Amadori13Maria Paola Costi14Ugo De Giorgi15Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSUnit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Campus Bio-Medico UniversityMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Morgagni-Pierantoni HospitalDepartment of Life Sciences, University of Modena and Reggio EmiliaMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSDepartment of Life Sciences, University of Modena and Reggio EmiliaMedical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSAbstract Background The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer. Methods Clinical data were reviewed in 29 patients who received FOLFOX-4 as more than third-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, and bolus 400 mg/m2 on day 1 of 5-fluorouracil, followed by a 22-h infusion of 600 mg/m2 of 5-fluorouracil for 2 consecutive days every 3 weeks. We also compared the efficacy and toxicity of FOLFOX-4 with that of topotecan, a standard treatment, given at a dosage of 1.5 mg/m2 every three weeks in 26 patients. Results The median age of enrolled patients was 60 years (range 33 to 85). A median of 4 cycles (range 1–17) of FOLFOX-4 were administered. Complete response and partial response were observed in one (3.5%) and 5 (17.2.2%) patients, respectively, while stable disease was reported in 8 (27.6%) patients. Among all patients, grade 3–4 anemia, neutropenia, and thrombocytopenia were observed in 0 (0%), 5 (17.2%), and 3 (10.3%) cases, respectively. Grade 3–4 fatigue was recorded in one (3.4%) patient and diarrhea in 2 (6.9%). Median PFS and OS were 2.8 months [95% confidence interval (CI) 1.7–4.9] and 6.2 months (95% CI 2.4–14.6), respectively. No significant differences in terms of efficacy and toxicity were observed between patients receiving FOLFOX-4 and those treated with topotecan. Conclusions The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings.http://link.springer.com/article/10.1186/s12885-018-5180-1FOLFOX-4FluorouracilTopotecanOvarian cancerPlatinum resistanceSurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vincenza Conteduca Giorgia Gurioli Lorena Rossi Emanuela Scarpi Cristian Lolli Giuseppe Schepisi Alberto Farolfi Delia De Lisi Valentina Gallà Salvatore Luca Burgio Cecilia Menna Andrea Amadori Lorena Losi Dino Amadori Maria Paola Costi Ugo De Giorgi |
spellingShingle |
Vincenza Conteduca Giorgia Gurioli Lorena Rossi Emanuela Scarpi Cristian Lolli Giuseppe Schepisi Alberto Farolfi Delia De Lisi Valentina Gallà Salvatore Luca Burgio Cecilia Menna Andrea Amadori Lorena Losi Dino Amadori Maria Paola Costi Ugo De Giorgi Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer BMC Cancer FOLFOX-4 Fluorouracil Topotecan Ovarian cancer Platinum resistance Survival |
author_facet |
Vincenza Conteduca Giorgia Gurioli Lorena Rossi Emanuela Scarpi Cristian Lolli Giuseppe Schepisi Alberto Farolfi Delia De Lisi Valentina Gallà Salvatore Luca Burgio Cecilia Menna Andrea Amadori Lorena Losi Dino Amadori Maria Paola Costi Ugo De Giorgi |
author_sort |
Vincenza Conteduca |
title |
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
title_short |
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
title_full |
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
title_fullStr |
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
title_full_unstemmed |
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
title_sort |
oxaliplatin plus leucovorin and 5-fluorouracil (folfox-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2018-12-01 |
description |
Abstract Background The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer. Methods Clinical data were reviewed in 29 patients who received FOLFOX-4 as more than third-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, and bolus 400 mg/m2 on day 1 of 5-fluorouracil, followed by a 22-h infusion of 600 mg/m2 of 5-fluorouracil for 2 consecutive days every 3 weeks. We also compared the efficacy and toxicity of FOLFOX-4 with that of topotecan, a standard treatment, given at a dosage of 1.5 mg/m2 every three weeks in 26 patients. Results The median age of enrolled patients was 60 years (range 33 to 85). A median of 4 cycles (range 1–17) of FOLFOX-4 were administered. Complete response and partial response were observed in one (3.5%) and 5 (17.2.2%) patients, respectively, while stable disease was reported in 8 (27.6%) patients. Among all patients, grade 3–4 anemia, neutropenia, and thrombocytopenia were observed in 0 (0%), 5 (17.2%), and 3 (10.3%) cases, respectively. Grade 3–4 fatigue was recorded in one (3.4%) patient and diarrhea in 2 (6.9%). Median PFS and OS were 2.8 months [95% confidence interval (CI) 1.7–4.9] and 6.2 months (95% CI 2.4–14.6), respectively. No significant differences in terms of efficacy and toxicity were observed between patients receiving FOLFOX-4 and those treated with topotecan. Conclusions The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings. |
topic |
FOLFOX-4 Fluorouracil Topotecan Ovarian cancer Platinum resistance Survival |
url |
http://link.springer.com/article/10.1186/s12885-018-5180-1 |
work_keys_str_mv |
AT vincenzaconteduca oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT giorgiagurioli oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT lorenarossi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT emanuelascarpi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT cristianlolli oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT giuseppeschepisi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT albertofarolfi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT deliadelisi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT valentinagalla oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT salvatorelucaburgio oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT ceciliamenna oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT andreaamadori oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT lorenalosi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT dinoamadori oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT mariapaolacosti oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer AT ugodegiorgi oxaliplatinplusleucovorinand5fluorouracilfolfox4asasalvagechemotherapyinheavilypretreatedplatinumresistantovariancancer |
_version_ |
1725176569359499264 |